Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | EBP | Q15125 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928199 | 0.92 | HRH3 (0.56) | CYP1A2LTA4HCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL873480 | 0.89 | CYP1A2 (0.57) | CYP1A2LTA4HCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10898516 | 0.86 | CYP1A2 (0.66) | CYP1A2LTA4HCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2424129 | 0.86 | KEAP1 (0.69) | CYP1A2LTA4HCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9706125 | 0.84 | EBP (0.72) | CYP1A2LTA4HCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL873540 | 0.83 | CYP1A2 (0.62) | CYP1A2LTA4HCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL23928219 | 0.83 | HRH3 (0.77) | LTA4HKCNH2HRH3KEAP1NFE2L2 | |
| SCHEMBL374223 | 0.82 | EBP (0.62) | CYP1A2LTA4HCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8432273 | 0.82 | CYP1A2 (0.70) | CYP1A2LTA4HCYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL10503798 | 0.82 | CYP2D6 (0.79) | CYP1A2LTA4HCYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | CYP1A2 290/4885LTA4H 1029/4885CYP2D6 1013/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | CYP1A2 290/4885LTA4H 1029/4885CYP2D6 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.